0001739614-22-000084.txt : 20220808 0001739614-22-000084.hdr.sgml : 20220808 20220808161910 ACCESSION NUMBER: 0001739614-22-000084 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20220808 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220808 DATE AS OF CHANGE: 20220808 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Inhibrx, Inc. CENTRAL INDEX KEY: 0001739614 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 824257312 STATE OF INCORPORATION: CA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39452 FILM NUMBER: 221144668 BUSINESS ADDRESS: STREET 1: 11025 N. TORREY PINES ROAD, SUITE 200 CITY: LA JOLLA STATE: CA ZIP: 92037 BUSINESS PHONE: (858) 795-4220 MAIL ADDRESS: STREET 1: 11025 N. TORREY PINES ROAD, SUITE 200 CITY: LA JOLLA STATE: CA ZIP: 92037 8-K 1 inhibrx-20220808.htm 8-K inhibrx-20220808
FALSE000173961400017396142022-08-082022-08-08

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 8, 2022
INHIBRX, INC.
(Exact name of registrant as specified in its charter)  
Delaware001-3945282-4257312
(State or other jurisdiction
of incorporation)
(Commission
File Number)
(IRS Employer
Identification No.)
11025 N. Torrey Pines Road, Suite 200
La Jolla, CA 92037
(Address of Principal Executive Offices and Zip Code)
Registrant’s telephone number, including area code: (858) 795-4220
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, par value $0.0001 per shareINBXThe Nasdaq Global Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company  
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  




Item 2.02    Results of Operations and Financial Condition
On August 8, 2022, Inhibrx, Inc. (the “Company”) issued a press release announcing its financial results for the three and six months ended June 30, 2022. A copy of the press release is furnished as Exhibit 99.1 to this report.

The information in Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 9.01.    Financial Statements and Exhibits.
(d) Exhibits.

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: August 8, 2022
INHIBRX, INC.
By:/s/ Kelly Deck
Name:Kelly Deck
Title:Chief Financial Officer


EX-99.1 2 exhibit99106302022.htm EX-99.1 Document
Exhibit 99.1
Inhibrx Reports Second Quarter 2022 Financial Results
and Recent Corporate Highlights

San Diego, CA, August 8, 2022 – Inhibrx, Inc. (Nasdaq: INBX), a biotechnology company with four clinical programs in development and a strong emerging pipeline, today reported financial results for the second quarter of 2022 and provided an update on recent corporate highlights.

Recent Corporate Highlights
On May 16, 2022, Inhibrx announced topline results from its Phase 1 clinical trial in INBRX-101 showing a favorable safety profile in patients with alpha-1 antitrypsin deficiency, or AATD, and demonstrating the potential to achieve normal functional alpha-1 antritrypsin levels with monthly dosing. The data shows the treatment was well tolerated with no severe or serious adverse events related to the study drug.
On June 30, 2022, Inhibrx announced completion of its Phase 1 dose escalation of INBRX-105 in combination with Keytruda® and the initiation of Part 4 of the Phase 1 clinical trial.
On June 30, 2022, Inhibrx announced the receipt of $60.0 million in gross proceeds under its Loan and Security Agreement with Oxford Finance LLC.

Financial Results
Cash and Cash Equivalents. As of June 30, 2022, Inhibrx had cash and cash equivalents of $176.4 million, compared to $131.3 million as of December 31, 2021.
R&D Expense. Research and development expenses were $29.9 million during the second quarter of 2022, compared to $17.9 million during the second quarter of 2021. During the period, Inhibrx’s clinical trial expenses increased, both for its Phase 1 trials as they continue to progress, including the purchase of Keytruda as used in combination studies in its INBRX-105 trial, as well as its continued expenses related to the INBRX-109 potentially registration-enabling Phase 2 trial which was initiated during the second quarter of 2021. The organization also incurred increased contract manufacturing expenses due to greater production run costs at its contract development and manufacturing organization partners, including drug substance batch manufacturing in preparation for a Phase 2 trial supply and pilot batch production for one of its preclinical candidates. Personnel-related costs also increased during the period, which is attributable to an increase in headcount as Inhibrx continues to expand its clinical operations and technical operations teams.
G&A Expense. General and administrative expenses were $5.4 million during the second quarter of 2022, compared to $2.9 million during the second quarter of 2021. This overall increase was primarily driven by an increase in additional personnel-related costs due to an increase in headcount as the organization builds out its commercial strategy team. In addition, Inhibrx incurred market research expenses related to its continued pre-commercialization efforts for INBRX-101 and INBRX-109.
Net Loss. Net loss was $37.7 million during the second quarter of 2022, or $0.97 per share, compared to $20.7 million during the second quarter of 2021, or $0.55 per share.


Exhibit 99.1
About the Inhibrx sdAb Platform
Inhibrx utilizes diverse methods of protein engineering in the construction of therapeutic candidates that can address the specific requirements of complex target and disease biology. A key tool for this effort is the Inhibrx proprietary single-domain antibody, or sdAb, platform, which enables the development of therapeutic candidates with attributes superior to other monoclonal antibody and fusion protein approaches. This platform allows the combination of multiple binding units in a single molecule, enabling the creation of therapeutic candidates with defined valency or multiple specificities that can achieve enhanced cell signaling or conditional activation. An additional benefit of this platform is that these optimized, multi-functional entities can be manufactured using the established processes that are commonly used to produce therapeutic proteins.

About Inhibrx, Inc.
Inhibrx is a clinical-stage biotechnology company focused on developing a broad pipeline of novel biologic therapeutic candidates in oncology and orphan diseases. Inhibrx utilizes diverse methods of protein engineering to address the specific requirements of complex target and disease biology, including its proprietary sdAb platform. Inhibrx has collaborations with 2seventy bio (formerly bluebird bio), Bristol-Myers Squibb and Chiesi Farmaceutici S.p.A. For more information, please visit www.inhibrx.com.

Forward Looking Statements
Inhibrx cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. These statements are based on Inhibrx’s current beliefs and expectations. These forward-looking statements include, but are not limited to, statements regarding: Inhibrx’s and its investigators’ judgments and beliefs regarding the strength of Inhibrx’s pipeline and the observed safety and efficacy to date of its therapeutic candidates; future clinical development of Inhibrx’s therapeutic candidates; evaluations and judgments regarding Inhibrx’s cash position; and statements and judgments regarding its partnership and relationship with Oxford. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in Inhibrx’s business, including, without limitation, risks and uncertainties regarding: the initiation, timing, progress and results of its preclinical studies and clinical trials, and its research and development programs; its ability to advance therapeutic candidates into, and successfully complete, clinical trials; its interpretation of preclinical data and initial, interim or preliminary data from its clinical trials, including interpretations regarding disease control and disease response; the timing or likelihood of regulatory filings and approvals; the successful commercialization of its therapeutic candidates, if approved; the pricing, coverage and reimbursement of its therapeutic candidates, if approved; its ability to utilize its technology platform to generate and advance additional therapeutic candidates; the implementation of its business model and strategic plans for its business and therapeutic candidates; its ability to successfully manufacture therapeutic candidates for clinical trials and commercial use, if approved; its ability to contract with third-party suppliers and manufacturers and their ability to perform adequately; the scope of protection it is able to establish and maintain for intellectual property rights covering its therapeutic candidates; its ability to enter into strategic partnerships and the potential benefits of these partnerships; its estimates regarding expenses, capital requirements and needs for additional financing and financial performance; its expectations regarding the impact of the COVID-19 pandemic on its business; and other risks described from time to time in the “Risk Factors” section of its filings


Exhibit 99.1
with the U.S. Securities and Exchange Commission, including those described in its Annual Report on Form 10-K as well as its Quarterly Reports on Form 10-Q, and supplemented from time to time by its Current Reports on Form 8-K. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Inhibrx undertakes no obligation to update these statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

Investor and Media Contact:
Kelly D. Deck
Chief Financial Officer
kelly@inhibrx.com
858-795-4260



Exhibit 99.1
Inhibrx, Inc.
Condensed Consolidated Statements of Operations
(In thousands, except per share data)
(unaudited)

THREE MONTHS ENDED
JUNE 30,
SIX MONTHS ENDED JUNE 30,
2022202120212020
Revenue:
License fee revenue$711 $918 $1,626 $1,781 
Grant revenue— 36 14 62 
Total revenue711 954 1,640 1,843 
Operating expenses:
Research and development29,906 17,902 54,801 34,340 
General and administrative5,402 2,853 10,453 5,862 
Total operating expenses35,308 20,755 65,254 40,202 
Loss from operations(34,597)(19,801)(63,614)(38,359)
Total other income (expense)(3,131)(909)(5,368)(1,638)
Provision for income taxes— 
Net loss$(37,732)$(20,710)$(68,986)$(39,999)
Net loss per share, basic and diluted$(0.97)$(0.55)$(1.77)$(1.06)
Weighted-average shares of common stock outstanding, basic and diluted39,040 37,824 39,029 37,780 





Exhibit 99.1
Inhibrx, Inc.
Condensed Consolidated Balance Sheets
(In thousands) 

JUNE 30,DECEMBER 31,
20222021
(unaudited)
Cash and cash equivalents$176,385 $131,301 
Other current assets5,238 7,811 
Non-current assets11,587 11,338 
Total assets$193,210 $150,450 
Debt, current and non-current$169,800 $70,470 
Other current liabilities24,201 22,454 
Other non-current liabilities4,131 5,143 
Total liabilities198,132 98,067 
Stockholders’ equity(4,922)52,383 
Total liabilities and stockholders’ equity$193,210 $150,450 

EX-101.SCH 3 inhibrx-20220808.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 inhibrx-20220808_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Pre-commencement Tender Offer Pre-commencement Tender Offer Amendment Flag Amendment Flag Entity Address, State or Province Entity Address, State or Province Entity Tax Identification Number Entity Tax Identification Number Title of 12(b) Security Title of 12(b) Security Entity File Number Entity File Number Written Communications Written Communications Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Entity Emerging Growth Company Entity Emerging Growth Company Trading Symbol Trading Symbol Document Period End Date Document Period End Date Soliciting Material Soliciting Material Document Type Document Type City Area Code City Area Code Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line One Entity Registrant Name Entity Registrant Name Entity Address, Address Line Two Entity Address, Address Line Two Local Phone Number Local Phone Number Entity Address, City or Town Entity Address, City or Town Cover [Abstract] Entity Address, Postal Zip Code Entity Address, Postal Zip Code Entity Central Index Key Entity Central Index Key Security Exchange Name Security Exchange Name EX-101.PRE 5 inhibrx-20220808_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 6 R1.htm IDEA: XBRL DOCUMENT v3.22.2
Cover
Aug. 08, 2022
Cover [Abstract]  
Document Type 8-K
Document Period End Date Aug. 08, 2022
Entity Registrant Name INHIBRX, INC.
Entity Incorporation, State or Country Code DE
Entity File Number 001-39452
Entity Tax Identification Number 82-4257312
Entity Address, Address Line One 11025 N. Torrey Pines Road
Entity Address, Address Line Two Suite 200
Entity Address, City or Town La Jolla
Entity Address, State or Province CA
Entity Address, Postal Zip Code 92037
City Area Code 858
Local Phone Number 795-4220
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.0001 per share
Trading Symbol INBX
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Amendment Flag false
Entity Central Index Key 0001739614
XML 7 inhibrx-20220808_htm.xml IDEA: XBRL DOCUMENT 0001739614 2022-08-08 2022-08-08 false 0001739614 8-K 2022-08-08 INHIBRX, INC. DE 001-39452 82-4257312 11025 N. Torrey Pines Road Suite 200 La Jolla CA 92037 858 795-4220 false false false false Common Stock, par value $0.0001 per share INBX NASDAQ false EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2 html 1 23 1 false 0 0 false 0 false false R1.htm 0001001 - Document - Cover Sheet http://inhibrx.namespace.com/role/Cover Cover Cover 1 false false All Reports Book All Reports inhibrx-20220808.htm exhibit99106302022.htm inhibrx-20220808.xsd inhibrx-20220808_lab.xml inhibrx-20220808_pre.xml http://xbrl.sec.gov/dei/2021 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "inhibrx-20220808.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "inhibrx-20220808.htm" ] }, "labelLink": { "local": [ "inhibrx-20220808_lab.xml" ] }, "presentationLink": { "local": [ "inhibrx-20220808_pre.xml" ] }, "schema": { "local": [ "inhibrx-20220808.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd" ] } }, "elementCount": 24, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 0, "nsprefix": "inhibrx", "nsuri": "http://inhibrx.namespace.com/20220808", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "inhibrx-20220808.htm", "contextRef": "ic939685ce8994567b23855a70d49073f_D20220808-20220808", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001001 - Document - Cover", "role": "http://inhibrx.namespace.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "inhibrx-20220808.htm", "contextRef": "ic939685ce8994567b23855a70d49073f_D20220808-20220808", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inhibrx.namespace.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inhibrx.namespace.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inhibrx.namespace.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inhibrx.namespace.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inhibrx.namespace.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inhibrx.namespace.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inhibrx.namespace.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inhibrx.namespace.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inhibrx.namespace.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inhibrx.namespace.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inhibrx.namespace.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inhibrx.namespace.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inhibrx.namespace.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inhibrx.namespace.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inhibrx.namespace.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inhibrx.namespace.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inhibrx.namespace.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inhibrx.namespace.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inhibrx.namespace.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inhibrx.namespace.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inhibrx.namespace.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inhibrx.namespace.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inhibrx.namespace.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 14 0001739614-22-000084-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001739614-22-000084-xbrl.zip M4$L#!!0 ( &2""%67^$Y401< &$! 0 6 97AH:6)I=#DY,3 V,S R M,#(R+FAT;>U=6W/;1K)^/[]B5O;)*E4@!8!WT7&5(BF)$UOVVLHF^[0U (;D MK$ ,@HLD[J_?[AZ !&^R*-$22,&NDB@"F.E[?]TS -[\[>SCZ>6_/IVS43+V MV:???WS_[I0=U(Z._FB<'AV=79ZQ7RX_O&?-NFFQRX@'L4RD"KA_='1^<< . M1DD2'A\=W=S/L&OX&?@GMO_^_-WVHU M=J;<="R"A+F1X(GP6!K+8,C^\$1\Q6JU[*Q3%4XB.1PES#9MF_VAHBMYS?7Q M1":^>)N/\^9(__WFB"9YXRAO\O:-)Z^9]'XXD#W>=1HMESOP/WWQ80>02GZVOB9.*+'P[&,JB-!,Y_W+'#I'\CO61T;)GF_Q_, MG9>(VZ3&?3D,CHE:.#I0P%MVV%6^BHY?F?2OCT=J SZ6_N3X[Y=R+&)V(6[8 M9S7FP=^-&"1W[+,(593$[(MP5>"Q?Z0\ M J*TUG^2 0]N1*RQ8&'SP)) !..@#4PL#,IALI@IR<&.TF':9Q\]\IJF_VNH=7RW:NN M;5E]EJG0@ ]NG1U>\-CC?WWWJM6%0Q<__OF]P3ASI$J$.PJ ^.&$N6H<\F#" M;F0R8@.51LP% J0+&@XC-8SX.&8R8)ZX%KX**4J@0#G((%(0),181$.,%J$, M!9)NL"076U%6#G>OAI%* Z^6B6T@\'__B82H/#YA$5DV!+C!U(RCS(P'*F+) M2+!5M#\1B3'Y6QF%Q_[*8H :/*> T-1+*1[T"/"6:^F!;8&WIJ&'048%8%X4 M>-QIX!E- T]]H\@S38,W]D'L>!(^:+P;) M<0._H:PA P\&/ZY9W2?@;U&EEMD!_C"BVNW^\U@[DC O&ZM1)UE\#-@'"&16 M6P=^(X_X8'4!.( +]I>H$,>:1;9(C9F$#Y]&/!;,F@7X),(("-$=@6,<7+.8#D4S0P <2_H3S0YY(4%"LLP;WPQ&O64 "P+YH M$L:4+P;2A7/&*L <@>, --@Q TA'<&52(]BW!U)2#4L M4-$8OAD 2QKB%F>)IM/XF)8R,F#<9.1/F*<0O=;9)8P-;LB)IYBF2A#?4@Z[ MX7"5\'%.7T0$>FF00+$8QHP$4HUZ4VG,N ??@.C@ #(="9\N ')QT#A)/9@U M2F'.RO2_J>G_FH)=-\SUMH]HQA=H,9BJBD8/5@$*C,'L>7XXM_H6FC1@U6GVR791V^ Z8*OY$)\@+;(F?L)CJQUL.QG9IQ&.9 M0,GK?E74JZWYE,]:L$5I6B'8! MU+ZV>_7>U+8]2&H9"->]AV*=KUUJWC,Z&UP,WG$V.R5$*.U-793Z59U^O%B+ M3*F5 ?:B8P&7@ ^-J#U3A'-T>HS>":-C%PLJB" 52":UK40<&SB(GWI3$E*0 M#UX-].7@#@=(899%!(B87A(9-.L,*=*\!LNK!_B-Q_/IO1D#"T5"/D)O5N[X MV(\:2ET+J: F JBVD%C-HYV)Y&8D0:U8KV30$P:]A^RQ^E'1D ?ROYHE$)=" MB:111/QF\B7:(^XF#(PP'< '/?:4$4]+=4A+ Q%*UTNI)F-1BD*+@7^>3,5 M0RUV"^>'GB,+K"L)H+HJ:@MK*1:G3IP0K')X A*8'P.+T$C Q7H4- ^^(+@X M#4.0,?5FI*^2;)P" WB5"D1>*L" 4W-TX3*)39RXSCX!>2H(A%_+E9IQG4DT M$Z2W;.U:=Q(%!#0Y:4+U-):YP?1"9 6725Q JPD:5)[%Z.L&F[N*!1/#QBDY3N=*4M2=IJEFW6BB>GRE/G3Q1GKH[*[&?!;@7 M]D^P:^^-P79TQ+D6B[FA-8-$&Z<&>[/,<#D"IU#72)@_\P0,^ ,6^5W'\O%@/J?"Q98'^\KK1J7),H0,/P-P!SQ<8311N$UN'2C M7%\O\V04$(^#-*8:(9,V#^$3=T<(R@E!Y+0!%/?S-9YB&0879?N*D/<7!:@M% 6/'Z HB=U%]R)RBYZ:2Y0B%H MS>D\6^42P8CK=0LL)F,('-S7%1*:T13E0-4CKXD6T/(<_G$ W UD)ORB0&0V M&Q".%6^8R#'8,I0D1%JML*Z&Q2A1AX0YHE!G33>"H31$C,6+C$<$6)0+)IMS M!!&?T)(* +51-:VK<"BSQ)SD,CUNN/+]/$%4QZJY_30EB$]V(3YA63DM!@'> M0"9;L[=GH%Q2BYKNX]%+O YXDS?=N(-&% F][.0 @I;8_;@/"IP]1SHIBH* MP8[SB!37V4-#*$+V[83#8CM!U_:%D(=))_>4>J%KC*#<][FC\NJ9_-N.:=UW M@D.S0[Q&1&#HCI\*1T8>?OV]P7Z,H*Y2?NW#!!AE7X!>Q]&M?'#U6+*?>#3F M+HE2LB_UL'Y29S]AJ% 1UB8X+-<5!7"&C%Q+@#H,]W)*36 =N-X%SP&N;CC( MY;U25RC^+PD8C59=R3S(Y:G6\T2E.I3%,UJQ/N,4V"FQ2^H/Q53&D7XB,00N MD4%07()*GP;#0"5LA.8043L&HVE,!P9:-#4_$\UL.FK8Q:)( %[@\,QOE_JF M6&R"Y!QP73'0#2"L--U$FVX^WOH9,P>!K =9>4JV#WE"%ZE&\=PIL]E>P@5J M\M:4#*XA3\@A!];C["C[3^H-,X[@M)S@F?CT'@K@9@C.ALOR"X-/XU.^!*\< MT/LU$)EM3"'>!Q GN(OXA^F]5[JGMSJ" 1>]/J +3'*S?MH"FEFDXZZA!"3_ MM-"+F_$\XW-)A;@PE1AB\M&@!:T:B@);U34%Q6E #)#+ M"QL=QWP"P7(P -A%.X,@(*/=01A%J#A:8^U90X66TF5\I6G#Y?4(G231O7(0 M$,I.+INK@T!BOB=O$)689,GFLN"W;O % YS?B6$PA#Y%C M)P68DD> C<9=,(,,^N@Q9I!L"M!Q284ZLXG(6K/:; K@_JZ 0PZ )H.TS@DB M=S5 %I[PLY!"_4M$X#ZDS>EBVO34++*NG6V!MSG++=0+ZVP>YULP-.UYLQ8K MX-.ORW2ZOD3Q#:(4)#:,@Q.]UB,Q"<\O-^7? &$R*@X%%:@N'#V ED"D/RF8 MFZM",86HNI"75$3GRS?38BB;3A)4T'(%K_&AGJ28BZA3('W4#HJUN>41? .! MT^T3%#J*NIQE@"F3A9Q6;;ZK&X"(J;[#-IHX$7)B[ E04X ):-:LZVU9U^_.>[LYK5 M8[@$)L; N@KF['>6/'4[02<13\1N)!W<[4]Y#A DI3#\G?5JJ/-L]C_#^0#0 MW1RUV%8?NYU%K\HC5-78?-F-S=4%11:/!/N]_J6>[Q;,\<7YK0O5,>284PAW M,HX)L!2W)B#^FAEKMN7@) A2VH:'=ZR@P?^$X\:0:: ZF+075:LH%/5&O349N.M:[#;)CXA;J-T:> MLT@/(&K?OZNP0BE!4O'E0.;5(V8?C,L1UBL@;4+8F22I)9%?7=@S,(;P/8"!,]]Z'&&'4!1M[[U,%. MS8]8&XNH',1=H<"^>]5N]@MMK9((KMOJUCJ]5JUIM\T';>,N!PBX_XW6S8,* M.#SY7OY,7%0[!ST-4[F$8!/N@>L$KME9_UALVZM/7;7L)9=;[377WK7L'. MMD>5JZP4'B:%._^&@<3#+*+27ZMAD%NTQR\>;GMI;.M4.;_'D M_I)_+CJ4]J6GCTODL9>_?#X_9Q\^7ES^\H6=7YR=GV&P^?7WBW.\'VT:=!;9 M?0&2^?+NSSFYL)5">:S=S$[-PG2B0C!,&P(OHP3)D-/^;HFN^)"#QW+\XB1G M;)N(3W5F5\A>/GQ*:XKQ&!PEYYP7_0S:6GY MYG"3GD=R+8)4S+>&[K#/=3QOS0&^)M3'C%$1^7Q$;NQ, _JWZ$R,?O=*[E7O MI8LM!S80V-LG#UMTKDWX-MDNA)+7CV*QO]CS*A5O'1J?D^?12Z1W>#\^G&??W;OKOB 4^N%FRR>K'<]88+UFY MO=:F&:!2[LXHUS+:3;-2[_ZJM]MLE%2]+V&Q-=ME6KA3K%IWK8BLUEVWN)MA M]:WGCT'G.QCG[9[1,W>_E;_G6K(ZH*5-B_5*2T^LI5;3Z)J[O_B_YUIJ-(W& M0RN7$J'7W7RG<#P:Z<^0*7[=12*ZY:P2O Z9;1,!^X_[1:""B_?FW3Z+1:E7[W M5;_MEF%7Z[3[J]^F:=@/;1U6*WG;N,$+WR-##X2;O33L,Y6JMU'U5I&NU%"U;Z$'L.G_&GEV0LR"#0D_/:!2Q6[N^Q8W7)8<@55=U?O MA)HJ/RJY@JJ]%?MWYDMH;ER(A/DJ7L(EWQ8METX,&S^HY_[\ESMN'38Z1J=A MEZ],>*)G2E5VO"=VC/MB++.RX\J.=]N.VUVCUVU7=ES9\6[;<:-G]'HE7#38 MZNU>Y@KSH[\EOK@J.:[UEE^(5 JX/WLAEL$<'DLW>Z,UOH+-^V:KS/OFLQOS M7W*?->M[O.^KLN(78\6M5F7%E17OMA5;]4X5BRLKWGDK-C>H97=LU^*.U@!_ MT!_"JW&@B@^%K@/H7;JN&H]5 0I]XJI-,$7Q"/']R@2'K#5)GMI; ,DZ:D4 M7T&;,U^P@!5'=W!Y$*IA\Y&/9]R&M'9O.]9+LI&.T;4?=^=?92/[;B,01^Q> M92.5C=P91SK=WYUFXX[Z'&[ MV39;W4';[+B]@?OOSL'6Z,OTU[%!P:&*)=Z4>AP)GY[,U<_>3D[*+5Z5:P'3\W8X;N )2.5PAA>_/U" MJ"HKT47GH? T\T.*B4"'S\-8'.*0^-6' M9SY5-[5?955K-G-VN$Z'%F*\/M:VZ^VNO?:P6;?6'KMK6*L-PW8?-.S=QYK- MAUWY56)[]QKV*YV!#9X#?<7:A2V:=LOV2" ?^L;&<(F+VG/-8O%'#Q@_@KE=?+O[/J\YK6*QW!T.J],V M&MT'/@2O1'VLRNIVRNH %S:>\WT"+^'.Z8_TF!4WC2((TXS'L5@.UO=J_^[N MK80MPVYL^@#7ZG[/)U92Q^AN_*K,\KVMM=2AX$(%M2T$@OOFTO+9F&49K6YG MYU'._FNIL7&\+A\JT,*VJ= N=5C0CV-;'1"J?84O8U^AU6L8MK7I&G>U2;8R MYC(:8ZS?@+*5X9^#Q)=0UY\))S%F=7W@L6 &[Q]3 M0>UI<-NE^-7&AXH_,'[M4+ZMK*Y,O'4@:7:>T>A>0@=FOAGK2^Y(7R;R<2_< MVL$2WVX:=O4BX=)KR088_<#[)TK4B-F!B%" ;H^."KN[!-#$Q]WO/.K9J=ICO3G-T24MBW)[);O2Z$C+*^^^WY[LW:&P6#?LWV Q?LRG?3 M^P["DR]XX_I(^2#)F)YLWNG3KK]D\L*PR6'3Z-D;/-6UPB5/C4MLH]'=$V#2 M,'<0F% /.KYWO+AG^%Y]X^S+7:K;LG3*[=,/6Y7>KHA*OJ.Y!'Z-DK'_]G]02P,$% @ 9(((5:W$,7?%$P %(, M !0 !I;FAI8G)X+3(P,C(P.# X+FAT;>T]:U?;NK+?SZ_0S;[W'+H62BR_ M'5K.HA#8Z6Y,&T+9R1>6+,G$P;&S;8BBA#NXF@F>!H$F1] M=,)%>H[\)!ZBDS@Y#RXHQOD[N_%HE@1G_0RIBJHN-29U77%\V_(T;"F6B>&) M8<_F"O9UQ19491[7V>99W3<-S;"(CDW/HEA7J8\=+G3L$\X][AE$Z'23UYGN M>;KA.(YIP "^XA'%-%0J/,,P"-<5.6T_@]7!"J/T7:6?9:-ZK3:93*H3K1HG M9S4"+]>FLD^EZ%2?>DD8+'25W^2=5471:D&49C1B8MX_#*+SKW27S1Y-K[IS M<3UXWC,5K'H67]2@ =Y0R;QC,,TPM"T,/>\;1#"LD.2I90F-4C].AC0#\L$( MQ,"*C;4;X]P%'=%N#'2U_#2X#4^P%E+[N_7QB/7%D.)E)$Q7L+" 7]EZ8UVW M _2U1:D*5E1,U'R0>DBCLW<5$>'CHPH06%"^_78H,HKDL%C\,PXNWE5VXR@# MML6=V0C 9,73NTHFIEDMIW=M^U__^M?;+,A"L1U$_7* TFX7B784'Z2BDLWH41P)@"*9UV5$DQ<> _ &1P.6TIWV%3]O8^ M3SYJ;MB]' W<@P^!NW<,_<]5]Z2KM ZZD^Z@,7$'Q[/NR9< ^I/6R6>EM6\K M']4>?,?,UO!+OSMH&EVUW3_L0)^##\/NX%SO==JA>]":=H>?8:R&XAX<7_"# M_< [.#9[G0]!:Z^EMO;V^X .;LM R80VUUCO6NVB*')ZWRG2\P MEQ'U.J.P-6Q.6I?=2>ND8<"\BGL9#N7Z6I?GL)[NU.WT!]W+8Z-+[,G'3B-K M'2G3CYWCR\.]S\8IL6VN:PXPFRT(UAU*L"G=B( ?9[M \(2&S8B+Z5]B]DK>^\@[72$OUQ3+]KB#+8_J6"<6QXYB M,.R 1'0XBB$5[85T'86$(SH*S2N+IIK3. "E*O! M>@;ZZ%TE#8:C4*K/_+M^DC/)DA*J3E. Y6UM<9@"A.MY2S#2>)SD3[G]JI?, M5W#(]S#??""1<][\*>#RV0]$@G* Q*WF:;?YUR(.EU_>GG^U./H(4!SS^1-8 MF"3; Y=C6P(EC9K4R\MM5V#R.[K.6^;/\TEJ"XB:8_4*C;4;*KT&BK_0_@4Z M[_$Z3DGEYCNEQ1@&$>X+Z1G5=;5J&:-L:Q+PK%\GBO)_E;SK]MMT1(&OO*0& M Q2?BW%61I,P8QH&9U&= 1)% B-DU O%O(,7)P [9G$8TE$JZO,/6W/+59A; MG+^T-:3)&<#GQ5D6#^L2-O 'LX#1L)PDGZ]HO@:[JA2@9X"CC,]G+INK>5,M MXZMMCEUUE+N;E2JY:JOE8R?S#B4"M5%6R=^#54DTO:MHE:6%9_$(!H*5H#0. M X[^ %BW1I3S(#JK*XCD(UQ/4;G6;C".VX>ZCQ]^Z?.^Y! ^T>MEK- MHZ/FH?N(2U#76L()3?O *UD<;:*]ZFX5XAE#=^X$NY0@R792?%[E\X7)Y_YA MNX4>T .AN7O[Y[UAT\C?N6Q='G;< M0>NR-74OS\")^Z+S/S^$/36\\ :C06O8D_--7.C?ZC"E==*63J.$3[YC@&L( M(S2T0Y@/1E%.#8_X"G,$YK;)L>[;&OCEFHY]4[,,YNBZY5N5;1O_M>JQO4KL M"Y/8]10\6*AVP^V@=N/38;OSY.W1IW&2CFF4H2Q&1X+)Q,B__R"FLD4T%">( M&!O\S7V\7G*C>0>[/\:R8A]E?2%7-$Z"+("!&U/6AS!*H!V6(6@FCJ8_>>K( M$$,"VQ:C.,G0QOQ94 @R1)HA<2%SJ$G>+/B;^J^P%9_R4*=1!$"+62(.W^ A MS-F7KV%.9W@&L&(1O2SC,FL-SDXYXZIM MRBAKL=%&8TK!*$KB2^.27!$=T12E(\%D=HVC($)!EB(PHV!KDC=HOJZ'!5F_ M%>1"7[XJQB>F&-=S")\-ZC52M4QG+=1_6YONF-_UYF\%K/5-3'T7!\^Y5!U- M)9^N,MP*A\2C7Z]GE5]BKIL1BQ,(!?+][:,,G/'=>!QER6PWYHN>NJP!D-L= MF1@E\84]O<:ENW=.7'BW*^%1/VN]O>YE]\0-#D^^ M]%LGQTL;?[$&XTZZP_9YJ]-2#CO'BCO\T.\.CN$]?NX.W'Y7;1J]D\:T]T7N MZ^XL;OPQ(H3E.R;V;!M\?-,TP<=W;"RH;VN&IA!;,R&,$R&=T$3A@-$]L#>O7'T_5S<7N5KQ/.KH7,.@HSVL&Y1A1R$Z]@4U MN* Z4U0AMV()UH!$=\>KKVS]D]FZ0Z?-Y=[\IY^"-W&N0F=\X MZXL$#<9)D/(@SPOG!000'P8WO8PWOY^PKXFIW7@X#-)TCAAI<5 ACB\7)\WV M$6H,1V$\$TF.E45MA=RX^F95]!,F#Z_4=SA.1IN6?CP >98Z_8=V M8[53AZD:,705FQ93P)O6&;8]DV+AF(PXNNYP'W0R(8IJ(+>*.G&2B!GZ!.A* M@78ITE_%1[OP\3#IQ)/G&8W_$!>!3T8=@QJ6P,SQ*=9]X"(;O"], MB07Q-&$^A"65[8\4?9!)PL>3]MQ).DP^)?%%D!]7>&&D^DQ.5\&HR'V]) I=PCI.%:XQ M3X>H1E?TW)9R['B,8:$ZB@_VE>NJ6=EV5$6S5FGTA H^UJN3VRBI+O>O/B4@ ME,&(AJ@Q%6R ))IGAS]SJ?BMFYWG_]]Q^V2JRM%&4B M%*-^' D4Y<'&IHS'PK&,$!!-! 6)XJ*.-AY0SJ21VH&I7IYD*>YEX]0"7T8U M/8*)9FI8!U6'J6\8&/P=C3M"UY@M,P>&O2Q7;QY2^7V,(0#\)!GC&>>$?L@H MJ:<&,:EB.Q8&A.E8URV";9O[V"$:I:K*F6V#%VHYX*$" E_+;)[;;O*#:^'; MBPUV^X*=Y_6$=#1*XE$2R!R9%T^1)\)X@H*BV' _3H;(QG\A/PBE-@Y24,V9 MB+C@LKHR#8;C,*.1B,=I.$,IS8+4G^5OEB_$'M"[2)24]8LW2C'&,$X"]FLV M;_.!J^*)?$]NX04R$976O\5TEQ3!H?"SHAX]Y[0@DCF;.I;?K(_P'4!*B(ZC M0)H?U#KZ,8P_H)X\28(,B"*S=^.HS$NE3_2LZV-H4?U4-SS&?;G=8PN(P@1A MV/.9/"IO>CKQ5$/EGJS <2Q=WUI6HD5ASNK_CUDL5)(PSJ M6U>-4LR6:H=ER? &L=#N?ANIFE*%CM]2%/TR!>T(=#\#_$5G+5"7$NK5"@0O MCD./@A[+0)N^.%EK34ZIH1NVY>M8TST&LJ: +VE[%O8)Y8[N^+ZABVYI->10- K MXX!7H5L0NLM3A1J.;6H,JS[Q,,1K#O:8HF/%%!KGW*",J<]*Z(#ZF-T@_[V6 MCN@F_5$L.B[KA#F1UM>I1#6V4S3L4A>9?%N69R>$@'F3O<43'000]TW M(&3WP.UT'(6JNJ_[E)B_N2QJ NL;;#U9+/O^!(-8Y!8&XS0+_-F/2.?/=1^N MG>XB]A4)1,^CU4.*B.3ZJXR% 4_UGZ^>GDU21[.JBF']]")M5:DZU@/4?MM5 MTUP/VGOJJDJ:Y%1<23BMDXQZ!C6%'7EC6''FD_41"VF:KE%>]"(PD]!\U^-H M-O3B<"-=I^QJ';SD]PS^MEASRU->.3N)N:$!A3KI!_#-M=;]E@+'$C>ENKL+ M=;\)-ZY8KH>N_2V-XHRH7JX-GJ6?6)3[=H?[87>P,^MVV,P]:0?N03OL=<)! M;Z^K'9ZT2/?R7.WMO>^[*^6^HT#"T=K[T'T'9U4$-U!TWM5/=4W?(\CH5I&1#S&1ZFQ/.Q[3!.',(, M16>5;>F]@R@<93$[WT0CFJ +&HX%^M_<-!,TDC>4];_O),>KC#RDC)3&H+ % MKP*RAH T%@7$4DU.%45@35,IUADCV+,<%1L6L3Q.-.YQ+@\ZO__[<7C_=['* MCV8]YD%E<9)_.1$A/8%G?PSPUPE/O)Z5Q\S0^6^ MXS.A.@(<5HA479IR^@\Z"&./AJA%DW.1W7^TY/L.7)?!_2.%\LV(RZ2'0-X, ML7P''8 ]!S=3Y"=+EK:W UF;A00@X$SZ]&=)/,GZ,G-$5<^#!%?@M! ML5FG&&CUEI_KRWTTM"&30=96OF$W[QSD]Q>,\OL+XB0?J;SN"$BF%A_7NSNH MZ#N?0^9FED:X,57U&[;E'XE:C=LQ_P-9M6>3M2W*1N<(.,C7OULL_S5ANU0= M,#LE7&<>\P3F#E%H!7PP?237Y7U$VLJ#R5LT5 MK-3D]$$OB5 P^?L%49RG)\>IR'L!G].$IT7-#[\]-SJ_P&V#7B5( M;VJPZI,1ZBLN>2V\>Q*%=W??%'V#*$NW38_B@KOKB0BIK+5>N7_Z&LC"^[]^ MA7H YSA;?>6^*ZN_]>ILJS)_IW^%UA$]$]A+!#W'U =FJM-P0F=II?: ]VM+ M$X*!JQ+*LGHZ'@(+SK;NVY\P].7]"?G-(U6D-S,Q+#2'6E74NS;@VB(=AUE> MC7\(6J_<^I+%]_M7:FTW!C6;GRM^&D;A,$*WW,6WB9K%_?GR ZNB#:E-93&^ MJFSMSGTD>");;\"'3<>@D2DH9WD4 01"4# '-(I ?[.\)!1PP M2.<5X \RY#A5(HU$[ID6-T96[T#]/1I@E6$?R6F5 5407?VBBXP-)'\BR9I7 M_O[N.$GD/FQYAR9TFQ?JWCPZL8 EFF642?1!H"*R>'.YE-<3-U$LZ=4'ES!W M :")"_ L^)Q)_" 4O&21G-)@L$$!BEPXKC8S[5MBF=NBCDU)43HL(+G)BS<[ MSQER\^H<_P1<"I2.O0',5_" 0&% O2 LILHGIV V"G@V82E)N:C@YIJNC_[# M WA'5[\7(5$OG9BRDOG.*LHR-KNYC!S*91]E4VY-B%%^ YV8Y@PN:Z9%)E$( M#A/,75Y,QQ:!2,>L7T*QRMUK,[!'V3EXA; ,7/*RG__;^E6<_8LNU[M/QSM5 MA53O4O+7JCP_#RF+'0H=7\I2^@,$^%5XWN!O'KMDI##M7+#R1HUZ+CRR%T3E M)28?LZ#E6ZBXM>BQ_W+_W"%55;6_QSVWJP8Q'N#R/%/YOC>_"JM=U6W]42[/ M*[#].+>+S$VT&U?7V'+X.1>L2 ?\*>%@3Z0L"48+;O/Z^_-%?*BNOTWRZY:_ MYCZ)=,]^+O$?!#5?"V)\_\'P\S53\I;>&H2*0JBV'AU 5/Q:60F/XT (KREY MM-//AGE9)<0X[:L8)X^TP M0R'KJY2I\LQ^1KBLO0SC%_AGA_K^3U9 MF#5_*TRIK&>PG\I)]Z/F@;O3.6Y_Y5>H[H*^S(IHC[=Y#^_V^ MWG?;L@>U]?+G1>JWY>1N4>@_S0=?EHNY9H7HTH\9K'J92SL! MQ/C*SL2/DN 74NN)!01K2LG[6?T;'.+GL*):6D-_B1!LU9Y@Y]]SS^IO1F)9 ML;4.D7^;*.^5^LL'0'XW&=_M!\*_L1E8W,^5K%'Y]LSVJ&M>S&?P!X+8^#7,FT" "&!P % &EN:&EB'-DS55;3]LP%'[OK_#R/.?60-N(%FD@I$G=)C$0O$U.?-):)'9F.S3\ M>VPG62_ H-(>)E6J?<[WG?MQSL[;JD2/(!43?.Y%?N@AX+F@C*_FWNW-%9YZ MYXO1Z.P3QO=?KI?H4N1-!5RC"PE$ T4;IM?HCH)Z0(44%;H3\H$]$HP7CG0A MZB?)5FN-XC".#[4R3<)9,9UD8SP))Z?8W'*<36F(BR2< HGSC";YYU5:G)Z, M3R91@D^S"<%)3 H\HY#@(J(TH]E)!$EGM%6IRM=0$602XRIMU=Q;:UVG0;#9 M;/S-V!=R%<1A& 7WWY8_'=3KL27C#WOH-I/E@!\'5IT1!0.<\37+9/N'T=]] M3BI0-0*]/?!_D<]+T8(V<*PJA92(_Z"OU.9:#:;!:U-U4-=(9=".[Z5]+*Z9KP0G<"(;.#I$/TU%,/FO%B' M5T;$_:5$YE*4[\Q34$M1@]0,U.XJ.0-K"<7?[SW&L)Q^9N*,J\'J[=1Y; \F^,'C$Z]RZ$ M^2!XR,INK[^^\\HXSQUC,#D8I5 PSMSPA>;!-3^$MQ\0C!SK+#C$'EAI%- ? M?.'.AQGVY![R%V).RKPIC^=MPWJ3U@N'"O9[%NPO6G??648GZ#9\,7H&4$L# M!!0 ( &2""%7RXC=LEPH !%A 8 :6YH:6)R>"TR,#(R,#@P.%]L M86(N>&ULS5QK;]LX%OW>7Z'-?MD%AC5?>K!H.^AFVD&QF;9H4W2PBX7!EQ)A M'"F0E2;Y]TO)=B+%DDU*MJ(OK6-?7YY[K,-#\4IZ_>O=U<+[J?-EDJ5O3M!+ M>.+I5&8J22_>G'P__P"BDU_?OGCQ^F\ _/FOKV?>;YF\N=)IX9WFFA=:>;=) M<>G]4'KYEQ?GV97W(\O_2GYR -Y67SK-KN_SY.*R\##$^.FG^2L*61R%@H 0 MA@$P?TD@(@5!3&&D.99"4?G+Q:LX\(D?(@H"$7) ,8\!4YJ"&"DEE/"1IJND MBR3]ZU7YC^!+[9GBTF7UYYN3RZ*X?C6;W=[>OKP3^>)EEE_,,(1DMHD^68?? M;<7?DBH:,<9FU:GFW5"=O7WC>BHX\6^BO.O;*_[]__=@Y))N5 M$;-47Y2_[!>=)YGZ5O"\..-"+PSZ*EMQ?ZW?G"R3J^N%WKQWF>NX/>TBSQM9 M2Y2L1(F"$N7?NP:;#8!_(+S%-M8#@*O*_70HC+LX_70PN.=F?M#'!UP;9C#D MU0'U/E5C';L/0PV&?GS$ASHLLH(O1C@L'H>I05Z4;YR95^MARD0[)M-JG/74 M78.J[PJ=*KV:+1NIO42].3&OYDHG\R^Y/LVNC.])79K?>?F=_',!41C M*B3@L?$N&L4QB.(H!@B22 A?^B&.YL7#D3W7*?C^;0.B&LEFF!.'*HL.M>9Z MF=WD\M'GKA9MYF5\JW2Z:);R*[V\YNLO&*SEDF %_ZU!"F0-JK?"ZE5@7\\> MB^O-ZV(DMA93)"J3#4"+6]3L)M;767MIL9AI-CJT%U!78'N N MNO=ID13W[Y0R/^G2G!44^G/^)<]^)@;BG#""$(P0D-JL&:AF 8@B*(SC:BF5 MX@(C9JO!70--39(KK-X:["]>!==0ZFT VZMT)[_[17LHUHZLX?Z$. M*M^9>#31VY17GP.LXOM.">?\[J,R\TL2)ZO]DT\W5\*L%C5'4FBI0(@B,R=0 MR4!$2 "(ID3R0&@E?+ MD\(>-@;,"EV91YX6]A2X/2_L^X+[Q/!-RYO<9$98G"?%0L^EC[2O4 PX5F:- M+LP:G0F! 8%FP2 ABZ$.;>>"I\FG)O\*E)?%'L+_$/_T-G#M5;_%WGZA#^'D MR-IVI<-)TEUU]U+Q5K+1A-M51EVKG3%]??M#LM!K)^&*J("% D@2^8#Z" '! M?0X@AY1&*( ^M=XP>YI\:O)<>TT)L*!^=(SCNC9,]/#9[9('6&LM MVXFVT[A?IX/).;)8'7EQ$NS.VGNIMCWC:-+= M65!=O[L#W47\9+O[XW)YH_-Z"T4'D"J?4:!C% !S(HP DYR#F!+$.4$RM-?S MOL&F)NVMOLL*\6'Z5-M4.W>K!A$X=L_*A;LAK:M.4@[1P-I._EQMK,XR=S2S MNK_3=TG^_DKG%TEZ\7N>W1:79JQKGM[/(X:(,N?( $LD T$!RR6%(@P5AA3 MDRNR/GG>,<[4IHOU\G2#U5N!]=9H71?M[=3:KM\'$S;.4MZ5JQ[+^IU,#%CA MM^<=>;&_L[CM=?_NW^ZO1+:8(Q5*/R004&S.S&G,,!!1' !? M15&,(LTUMNZI-3)/3>AK<-X*G;VPFW3MEW)O$HZ]0V97OY-86VOM)<]FIM$$ MV5I 78+M >ZBVUP]_7#)X&^\T$9\0F'&( A\2@$-50 893[ E/J$\(@H2FS% MUSK"U$3X"DE "GT<:4*HIB 0R_VC)8A&@4!!H MW7;:2C\U"3\B]#80'9I.V^Q9M)T&<7)DW;K0X=9TZJRZ7]MI.]UXC:?.4AJM MI^ZH_GY[;KXZURR4.E;:"#0(S4(7&IN%U =^:"P7Z@ ):KT=5D\\-6D^>$@) MSMU2*Z[LG=25@;$,=&?QO5RS7ND@LZP2C>Z1=?AMUMCXW%UJI^5%7[GFIYG2 M\U H%D'L Q)(7NX\8\ "&8.0^)'O8Q$H:;VBK2>>FM1.J^L+#3BO1&>OM099 M^[76EX(C:\VR>B>QM97:2VR-1*.)K0U^76RMG_?=P?V8RBR_SO*JDU1=:7F: MW:1%?E\=5F8]JH2O0\!9>9U% !6(<""!X(2@2"$&D>,ED3O'FYHTU[N4#<@QY\Q,*J2\V)H*4 !"4,-0PI)$/:[]Z(^RD2GDH?["-8O MO!*L]SGM>]]%@UC;66,@7>/,%>Y,];_AHHV)X7=;-+(^SZT6;85UWF?1&MQ7 M^%_U1;(LDAZ/;2!VCY2<*19=Q>SK:".^(.Y]IXCE#$ MH8(2P$"94P'J*\"1X.;LG/F,"\DYM#X=[QQEHC)N]Z+SVVRX:^,!KNU$UW.Z M]BZF#N+:^"BNC9_?M;&+:^,!PB^?);7X15 YULLMHC;K^>MU* M-II,N\JHJ[,S9J ;E]M^G_/S[#:=2X8U%- 'W.<44!5AP%6I4@P9PX$FF/<[ M@WX<8VH2?>HOU;YQEGLEUIXN7"/4T8/[T32R ULQU-]]MSD8[KVUG,_CO-M% M=?IN2VB/AE?V4^?O1+ETEX5-$Z<>/Z%CK\+E_7>#['\'ZN.T5=NOD=/(-%XG MIZV 1BNG-6"@47S)E@5?_">YKEH)$)DS-Q8S(,V)&J"1]$$$0PVPCZ#&2D3, M5[V\HC',U.UB!=8S:'MU:UJ9=32-WGR-[!NV5/6WCE8FAKM',^WS&$AK:9T> MTA[=5_ZG.C7SR.)CJO3=O_7]/ HP"HB[H_H!NGZ:<61)=Q2TK>:N MP/[/H7E_)R_-[Z>K;?\HIF&$102,4X> #@& D8FW=.VD;8&HR MWF#T-B =>R>M).[7\%!JCBQA1U9Z/96FK?1!3Z9I)!S]Z31MY;0]H:8UKDN\ M=<;/S*NW+S;O)*MGZ+]]\7]02P,$% @ 9(((5:]].<;;!@ S, !@ M !I;FAI8G)X+3(P,C(P.# X7W!R92YX;6S5F]MNVT@2AN_S%%K-[;;5)_;! MB#WP>I*%L9Z)D7B0P=X(?:B6B$BDT*1C^^VW*-M)?,@,Q]3"S(TE44U6]5\? MNZM*].N?K]:KR6?(35E7!U.V1Z<3J$(=RVIQ,/W]_"TQTY\/7[UZ_0]"_OC7 M^]/)+W6X6$/53HXSN!;BY+)LEY./$9I/DY3K]>1CG3^5GQTAA]N3CNO-=2X7 MRW;"*>BJK#[M=W^\:V""DZN:[<>#Z;)M-_NSV>7EY=Z5SZN] M.B]FG%(QNQL]O1U^]6C\I=B.9M;:V?;;+T.;\JF!>%DV^^/7TP]A"6M'RJII M714Z TVYWVP/GM;!M5O-_]*OR7='=)_(W3#2'2*,$\'VKIHX/7PUF=S(D>L5 MO(;^!@VI3K MS0KNCBTSI(/I[15(%UMJJ.D,_W1S[NRK_4V&!I'9SO<4#]Q>HC/T3%_@JH4J MPLTD[\RLZG!OT*J3N/YRYLIY6&V/SB.4\^U5CWS39A?:.;74>:D\ 2\8D59& MX@1+1(DB!J"<:6ON3[WSNT''MQ%I(.PMZL\SO#!&AK/N32?*-A(_/3)W(\[S M_+Z[ <]Q[%QQJ83$NX>&:(A4UA"O@\9[@P6F%1.:\T%N?VOMOM??!O4HATF= M(V1<0>[,N1SN!?@QO;WD3ENY/;SJS%=16V(W<1\3/(91W?5/$77'CGVH=D!3#"0XA$:H8L4)1!IIV$_I[97@SP\3/P?"U?&(8W55NVU^]A479*5.UON%[."VU<=,83 MYQ,ETNE$'-.!!*6M!R6$U6$0"T]9[86"&"\*@Y4&X MOJC:?'U<1YAS$8U1*(97(1%9&$5,X00IH,#%CSEGH]\!&'_J1"].Y-@YV9W. MH\#F;;F"WR[6'O(\6.O0RX)0+7 GC$83$Z0B40!8*WP,>MA&\M!B+R"*L0/Q M3 5'$?US=W424:LRE3=5R.U$>(J&)>E)XJ")E!8G(H0B3$LAO!12,[8#%+YC MOA<7:NQ<[$+;44!R%".&H+E]P;H-V%S; $)R30*W@L@4'5;KVA*045%&H0"U MBT3C"=.]X-!CAV.HIB,%@V/>Q 0U'KU6S*(LX(AQ1A!&->-)&\J,^+^ P7N! M87X\,/Z>IF,"XQC?OLOG]64UYR%:90,N>CJ%;F"D&\-4!H M47CC*&/\:X"& W+/=C\\1MSGW)&L+PQ'M^H=97!;OY5'?S%_QO0()$JA*=;7 M,1#*5#"*4R808=S:G(_&@M8B*)RJ&I0I/FNT'PHB[EL/%?&$:/M2K,I1M62U^ MQ00GEVXUYQ*"$DP173"#+',@/A4,I=&1%4XK*X>A\-AF/PY&W*P<*.,+0W"6 MH2,8,+'=_G+;_>B?WR7T8RX@Z4!Q80LQ4")YM\1Q%0D#Z@('7X!S@V#XONU^ M4(RX4[DC6<<%QTG37$#^=B[&0O01L/9)S!/I0B)8.W=J16T*:85,PXJ(O_*@ M'R@C[EKN5.*7WE @7."F>,VX/R_;%:OQPO?8U[H&4.HGI#KH;5%<(%Y@1XX*7 MA++16$<+/JQ??<]E#D]9[??DU(B[CH.E'$6W\N+]LE;FX;5UW/ M"VF$]TFC\U1B783;F).%(#%X34.AC16[^%WS2>/]P!A]OW&XL"_,QQ%F.+'+ M,LI+.&V.@L[G76):NHTFS8<]5/FNU'P8B[ MC\/%W!D-KV>/1#S% X>O;K_H_G3_-7'XZG]02P$"% ,4 " !D@@A5E_A. M5$$7 !A 0$ %@ @ $ 97AH:6)I=#DY,3 V,S R,#(R M+FAT;5!+ 0(4 Q0 ( &2""%6MQ#%WQ1, !2# 4 " M 747 !I;FAI8G)X+3(P,C(P.# X+FAT;5!+ 0(4 Q0 ( &2""%5[X-"TR,#(R,#@P.%]P <&UL4$L%!@ % 4 5 $ .D_ $! end